Immunotherapy biomarker discovery could benefit thousands with Type 1 diabetes

August 03, 2020

Scientists at UCL have discovered new biomarkers, which may identify those people with Type 1 diabetes who would benefit from the immunotherapy drug Abatacept, a finding which could eventually help thousands manage the disease more effectively.

Type 1 diabetes is an autoimmune disease, which means it is caused by the body's own immune system attacking healthy body tissues. People with the condition are unable to produce the hormone insulin, which is essential to control and use glucose as energy.

Abatacept is an immunosuppressive drug that subdues the aberrant immune response in people with autoimmune diseases, and identifying a biomarker will enable clinicians to give the drug to those who would positively respond.

The research group, led by Professor Lucy Walker (UCL Institute of Immunity & Transplantation), built on their discovery in 2014, which found that certain immune cells, known as 'follicular helper T cells' (Tfh), can cause Type 1 diabetes by triggering the destruction of insulin-producing cells in the pancreas.

In this latest study, published in Nature Immunology, researchers at UCL in collaboration with scientists from King's College London and AstraZeneca, wanted to find out why some people with Type 1 diabetes responded well to Abatacept, while others did not.

Explaining the study's focus, Professor Walker said: "Abatacept is already widely used to treat other autoimmune conditions, including rheumatoid arthritis.

"Early tests in people with Type 1 diabetes have found the drug is not suitable for routine use because the response is very variable - some people benefit a lot, while others not at all. "Being able to tell in advance who is likely to respond may reignite interest in this therapy for those with diabetes."

For the study, blood samples from people with Type 1 diabetes, who had taken part in a clinical trial of Abatacept were studied. The team discovered that the numbers of Tfh cells were reduced by Abatacept treatment and the cells' phenotype (biochemical characteristics) had been changed.

Machine learning was then used to compare blood samples from people who showed a good response to Abatacept with those who showed a poor response.

To the team's surprise, the machine learning algorithm was able to detect differences in the profile of the Tfh cells, even before treatment, which could be used as biomarkers to establish whether someone was likely to respond to Abatacept.

Professor Walker said: "Our new work suggests that by analysing these T cells, and looking at the markers they express, we can make predictions about how well people will respond to Abatacept.

"The next step will be to test this in more people and explore whether it works for other therapies and other autoimmune diseases. "New improved versions of Abatacept have now been developed and it will be particularly exciting to see if the biomarker approach is applicable to these."

In the UK, there are around 400,000 people with the Type 1 diabetes, including 29,000 children. As those with the condition cannot produce insulin, glucose builds up in the bloodstream, and over time can cause serious kidney, heart and eye damage.

In 1999, Professor Walker identified signals that controlled 'follicular helper T cell' behaviour, and later found that these cells appear in high numbers in those people with Type 1 diabetes.

She added: "The project has been years in the making and has relied heavily on collaboration between researchers, clinicians, bioinformaticians and industry partners."

Professor Walker's research team are part of the UCL Institute of Immunity & Transplantation, based at the Royal Free hospital, London. The project received funding from Diabetes UK, AstraZeneca, the Medical Research Council and the Rosetrees Trust.
-end-
Notes to Editors

For more information or to speak to the researchers involved, please contact Henry Killworth, UCL Media Relations. T: +44 (0) 7881 833274 E: h.killworth@ucl.ac.uk

Natalie Edner, Frank Heuts, Niclas Thomas, Chun Jing Wang, Lina Petersone, Rupert Kenefeck, Alexandros Kogimtzis, Vitalijs Ovcinnikovs, Ellen Ross, Elisavet Ntavli, Yassin Elfaki, Martin Eichmann, Roman Baptista, Philip Ambery, Lutz Jermutus, Mark Peakman, Miranda Rosenthal and Lucy S. K. Walker, 'Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes', will be published in Nature Immunology Monday 3 August 2020, 4pm UK Time/ / 11am Eastern Time.

The DOI for this paper will be: 10.1038/s41590-020-0744-z

About UCL - London's Global University

UCL is a diverse community with the freedom to challenge and think differently.

Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.

We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.

We have a progressive and integrated approach to our teaching and research - championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.

For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.

We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.

http://www.ucl.ac.uk| Follow @uclnews on Twitter | Watch our YouTube channel | Listen to UCL podcasts on SoundCloud | Find out what's on at UCL Minds | #MadeAtUCL

Find out how UCL is helping lead the global fight against COVID-19 http://www.ucl.ac.uk/covid-19-research

University College London

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.